New-generation anticoagulant agents pose risks in treatment of acute coronary syndromes

The potential ischemic benefits of novel oral antiplatelet therapy following an acute coronary syndrome (ACS) may be offset by a significant increase in major bleeding events, according to a meta-analysis recently published in the Archives of Internal Medicine.


“We are already exposing these patients to several drugs that can produce bleeding complications. Adding oral anticoagulants, albeit new generation, is expected to increase this risk further.”
-K. Sarat Chandra, MD, DM, cardiologist and a member of the mdCurrent-India Editorial Advisory Board, Hyderabad, India


India has the greatest number of ACS events in the world, according to a study published in 2008 in The Lancet. That study found that patients who experience ACS in India have a...

Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in Cardiovascular, Pharmacology, Primary Care and tagged , , , , , , , , , , , , , , , . Volume: .

Post a Comment

You must be logged in to post a comment.